Skip to content
FibroGen, Inc. logo — Committed to being a place where our people and science thri...

FibroGen, Inc.

Committed to being a place where our people and science thrive.

Founded 1993 United States San Francisco, United States 347 employees Post-IPO Equity Total: $308.02M Biopharma, Biotechnology +2

General Information

Company Name FibroGen, Inc.
Founded Year 1993
Location United States San Francisco, United States
Founders / Decision Makers
Team member Team member Team member
Employees 347
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Business Model B2B, B2C
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with FibroGen, Inc.. To contact FibroGen, Inc., visit fibrogen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FibroGen, Inc. compare?

A PDF of FibroGen, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FibroGen, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FibroGen, Inc.

FibroGen, Inc., founded in 1993, is a United States-based company operating in the biopharma and biotechnology sectors. The company is dedicated to pioneering first-in-class therapeutics targeting significant unmet medical needs globally, with a focus on areas such as anemia, fibrotic disease, and cancer.

Leveraging their expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology, FibroGen is advancing innovative treatments like Pamrevlumab, currently in clinical trials for pancreatic cancer and Duchenne muscular dystrophy, and Roxadustat, an approved oral medication for anemia of chronic kidney disease.

In addition to its established portfolio, the company is expanding into immuno-oncology and autoimmune research. Despite being a mature entity with its last investment as a Post-IPO Equity investment on 14 August 2017, FibroGen continues to be a dynamic player with substantial potential for impacting global health through its extensive R&D pipelines and commitment to innovation where "people and science thrive."

Business keywords: Connective Tissue Growth Factor, Hypoxia-Inducible Factor Biology, Monoclonal Antibodies, HIF-PH Inhibitors, Anemia Treatment, Fibrotic Disease, Cancer Therapeutics, Pancreatic Cancer Treatment, Duchenne Muscular Dystrophy, Immuno-Oncology, Autoimmune Disorders, Biotechnology Research, Drug Development, Clinical Development

Services & Products

R&D Pipeline Management
Clinical Trials Execution
Drug Development
Scientific Research and Innovation

Target Customers

Healthcare Providers Medical Researchers Pharmaceutical Investors Patients with Prostate Cancer Patients with Anemia

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
14 Aug 2017
Post IPO Equity $120.00M -
06 Apr 2017
Post IPO Equity Undisclosed 1
Hony Capital
01 Apr 2017
Post IPO Equity $62.00M 1
AstraZeneca
08 Jul 2016
Venture Round $20.00M -
19 Nov 2014
Private Equity Round $6.02M -
27 Jul 2012
Venture Round $100.00M 10
Goldman Sachs, T. Rowe Price +8
17 Feb 2005

FibroGen, Inc. Alternatives & Competitors

View All Alternatives
FibroGen, Inc. vs
Curis
Curis United States

Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of...

Post-IPO Equity
133 employees
Biotechnology, Health Care
FibroGen, Inc. vs

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
FibroGen, Inc. vs
Arcus Biosciences
Arcus Biosciences United States

Biopharmaceutical company developing differentiated molecules and combination therapies for cancer a...

IPO
633 employees
Biopharma, Biotechnology

FAQ About FibroGen, Inc.

Committed to being a place where our people and science thrive.
FibroGen, Inc. was founded in 1993.
FibroGen, Inc. is headquartered in San Francisco, United States.
FibroGen, Inc. operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on Connective Tissue Growth Factor, Hypoxia-Inducible Factor Biology, Monoclonal Antibodies and HIF-PH Inhibitors. Its customers include Healthcare Providers, Medical Researchers and Pharmaceutical Investors.
FibroGen, Inc. has a B2B and B2C business model. Its revenue comes from Licensing and Product Sales.
FibroGen, Inc. has approximately 347 employees.
FibroGen, Inc. has completed 7 funding rounds, raising a total of $308.02M. The latest funding stage is Post-IPO Equity.
FibroGen, Inc. offers: R&D Pipeline Management, Clinical Trials Execution, Drug Development, Scientific Research and Innovation.
Top alternatives and competitors to FibroGen, Inc. include Curis, Farcast Biosciences, Arcus Biosciences, Xencor, Elixirgen Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FibroGen, Inc. and Curis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FibroGen, Inc., https://bouncewatch.com/company/fibrogen-inc, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout